RNA疫苗  

RNA vaccines

作　　者：吴浩飞[1] 罗丹(综述)[2] 黄仕和[3] 闭兰(审校)[2] 

机构地区：[1]武汉生物制品研究所有限责任公司质量保证,430207 [2]武汉生物制品研究所有限责任公司免疫研究室,430207 [3]武汉生物制品研究所有限责任公司科研图书情报室,430207

出　　处：《国际生物制品学杂志》2013年第2期91-95,共5页International Journal of Biologicals

摘　　要：核酸疫苗包括质粒DNA、病毒载体和RNA疫苗，极有可能促成新一代疫苗生产方式的变革，因为它既综合了减毒活疫苗的优势，又避免了减毒活疫苗的安全性及生产复杂性等问题。RNA疫苗，包括基于信使RNA（mRNA）和自我扩增RNA复制子的疫苗，能克服质粒DNA和病毒载体的局限性。随着RNA疫苗的生产可行性及成本问题的解决，RNA疫苗商业化的曙光已经显现。RNA疫苗概念在人体中已得到验证，其进一步开发为商业化产品的前景令人鼓舞。Nucleic acid vaccines consist of plasmid DNA, viral vectors and RNA vaccines. Since the nucleic acid vaccines combine the benefits of live-attenuated vaccines, and avoid the problems of complication related to live-attenuated vaccine safety and production, they may change the way that next generation vaccines are produced. RNA vaccines, including those based on messenger RNA （mRNA） and self-amplifying RNA replicons, have the potential to break through the limitations of plasmid DNA and viral vectors. With solving the issue of cost and manufacturing feasibility , the commercialization of RNA vaccines has become promising. The concept of RNA vaccines has been demonstrated in humans, and the prospects for further development into commercial products are very encouraging.

关 键 词：质粒DNA 病毒载体 RNA疫苗 

分 类 号：R392.1[医药卫生—免疫学]